Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APR NYSE:BVS NASDAQ:DSGN NYSE:TBA NASDAQ:TDUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPRApria$37.50$37.45$22.36▼$40.00$1.34BN/A682,285 shsN/ABVSBioventus$6.88-0.7%$7.04$5.81▼$14.38$572.97M0.81382,012 shs194,289 shsDSGNDesign Therapeutics$6.17-8.0%$5.95$2.60▼$7.77$382.12M1.68244,661 shs113,064 shsTBAThoma Bravo Advantage$9.61$9.72▼$13.19$1.04BN/A1.40 million shs1.83 million shsTDUPThredUp$9.11-2.9%$10.23$0.50▼$12.28$1.16B1.711.93 million shs1.21 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPRApria0.00%0.00%0.00%0.00%0.00%BVSBioventus-0.72%+4.40%+0.58%+9.90%-46.75%DSGNDesign Therapeutics-8.05%-13.34%+5.47%+55.03%+9.20%TBAThoma Bravo Advantage0.00%0.00%0.00%0.00%0.00%TDUPThredUp-2.88%-0.55%-10.69%+24.28%+1,023.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPRApria$37.50$37.45$22.36▼$40.00$1.34BN/A682,285 shsN/ABVSBioventus$6.88-0.7%$7.04$5.81▼$14.38$572.97M0.81382,012 shs194,289 shsDSGNDesign Therapeutics$6.17-8.0%$5.95$2.60▼$7.77$382.12M1.68244,661 shs113,064 shsTBAThoma Bravo Advantage$9.61$9.72▼$13.19$1.04BN/A1.40 million shs1.83 million shsTDUPThredUp$9.11-2.9%$10.23$0.50▼$12.28$1.16B1.711.93 million shs1.21 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPRApria0.00%0.00%0.00%0.00%0.00%BVSBioventus-0.72%+4.40%+0.58%+9.90%-46.75%DSGNDesign Therapeutics-8.05%-13.34%+5.47%+55.03%+9.20%TBAThoma Bravo Advantage0.00%0.00%0.00%0.00%0.00%TDUPThredUp-2.88%-0.55%-10.69%+24.28%+1,023.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPRApria 0.00N/AN/AN/ABVSBioventus 2.75Moderate Buy$13.7599.85% UpsideDSGNDesign Therapeutics 1.00SellN/AN/ATBAThoma Bravo Advantage 0.00N/AN/AN/ATDUPThredUp 2.67Moderate Buy$13.0042.70% UpsideCurrent Analyst Ratings BreakdownLatest DSGN, APR, TBA, TDUP, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TDUPThredUpWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TDUPThredUpWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/4/2025TDUPThredUpNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/5/2025TDUPThredUpNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.008/5/2025TDUPThredUpWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $13.008/5/2025TDUPThredUpTelsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$9.00 ➝ $12.007/29/2025TDUPThredUpTelsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.007/21/2025TDUPThredUpNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/21/2025TDUPThredUpNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPRApria$1.15B1.17$5.27 per share7.12$1.12 per share33.48BVSBioventus$564.14M1.01$0.55 per share12.58$2.80 per share2.46DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ATBAThoma Bravo AdvantageN/AN/AN/AN/AN/AN/ATDUPThredUp$260.03M4.31N/AN/A$0.48 per share18.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPRApria$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/ABVSBioventus-$156.23MN/AN/A14.96N/A-7.11%15.61%4.01%N/ADSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)TBAThoma Bravo Advantage-$30KN/A0.00N/AN/AN/AN/AN/AN/ATDUPThredUp-$76.99M-$0.49N/AN/AN/A-19.66%-71.49%-23.61%11/3/2025 (Estimated)Latest DSGN, APR, TBA, TDUP, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025DSGNDesign Therapeutics-$0.34N/AN/AN/AN/AN/A11/3/2025Q3 2025TDUPThredUp-$0.04N/AN/AN/A$77.34 millionN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPRApriaN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ATBAThoma Bravo AdvantageN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPRApria8.581.091.06BVSBioventus1.851.410.99DSGNDesign TherapeuticsN/A25.1325.13TBAThoma Bravo AdvantageN/A1.381.38TDUPThredUp0.270.960.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPRApriaN/ABVSBioventus62.94%DSGNDesign Therapeutics56.64%TBAThoma Bravo AdvantageN/ATDUPThredUp89.08%Insider OwnershipCompanyInsider OwnershipAPRApriaN/ABVSBioventus33.00%DSGNDesign Therapeutics23.50%TBAThoma Bravo AdvantageN/ATDUPThredUp27.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPRApria6,08035.65 millionN/ANot OptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableTBAThoma Bravo AdvantageN/A102.40 millionN/ANot OptionableTDUPThredUp1,630123.16 million89.91 millionOptionableDSGN, APR, TBA, TDUP, and BVS HeadlinesRecent News About These CompaniesThredUp Report Reveals 40% of Holiday Budgets Will Go to Secondhand GiftsOctober 16 at 12:47 PM | finance.yahoo.comApparel and Accessories Stocks Q2 Recap: Benchmarking ThredUp (NASDAQ:TDUP)October 13, 2025 | msn.comBlair William & Co. IL Sells 324,680 Shares of ThredUp Inc. $TDUPOctober 11, 2025 | marketbeat.comAnalysts Set ThredUp Inc. (NASDAQ:TDUP) Price Target at $13.00October 10, 2025 | americanbankingnews.comThredUp's (TDUP) Sell (E+) Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comThredUp to Report Third Quarter 2025 Financial Results on November 3, 2025October 7, 2025 | globenewswire.comSimplicity Wealth LLC Boosts Holdings in ThredUp Inc. $TDUPOctober 7, 2025 | marketbeat.comThredUp Inc. (NASDAQ:TDUP) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 5, 2025 | marketbeat.comBloombergSen Inc. Sells 626,365 Shares of ThredUp Inc. $TDUPOctober 2, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Stock Position in ThredUp Inc. $TDUPSeptember 28, 2025 | marketbeat.comthredUP (TDUP) Receives a Buy from Northland SecuritiesSeptember 23, 2025 | theglobeandmail.comThredUp Unveils New Brand Identity to Mark Resale’s Mainstream RevolutionSeptember 22, 2025 | finance.yahoo.comThredUp (NASDAQ:TDUP) Stock Price Down 5.6% - Time to Sell?September 22, 2025 | marketbeat.comThredUp Unveils New Brand Identity to Mark Resale's Mainstream RevolutionSeptember 22, 2025 | businesswire.com3 of Wall Street’s Favorite Stocks We Find RiskySeptember 19, 2025 | msn.comWhy ThredUp (TDUP) Stock Is Up TodaySeptember 19, 2025 | msn.comThredUp (NASDAQ:TDUP) Stock Price Down 5% - Time to Sell?September 17, 2025 | marketbeat.comByrne Asset Management LLC Takes Position in ThredUp Inc. $TDUPSeptember 17, 2025 | marketbeat.comOptimist Fund’s Investment Thesis for ThredUp (TDUP) is Paying OffSeptember 16, 2025 | finance.yahoo.comThredUp: Attractive Buy As Resale Market Heats UpSeptember 10, 2025 | seekingalpha.comThredUp to Participate in Wells Fargo ConferenceSeptember 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Semtech Stock Is Rallying After Its NVIDIA SetbackBy Leo Miller | October 7, 2025DSGN, APR, TBA, TDUP, and BVS Company DescriptionsApria NYSE:APRApria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.Bioventus NYSE:BVS$6.88 -0.05 (-0.72%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$6.88 +0.00 (+0.07%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Design Therapeutics NASDAQ:DSGN$6.17 -0.54 (-8.05%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$5.65 -0.52 (-8.43%) As of 10/16/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Thoma Bravo Advantage NYSE:TBAThoma Bravo Advantage does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Chicago, Illinois.ThredUp NASDAQ:TDUP$9.11 -0.27 (-2.88%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$9.06 -0.05 (-0.60%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Energy Crunch Ahead: 3 Natural Gas Stocks Set to Gain Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
